Hepatitis B: Epidemiology and prevention in developing countries

Elisabetta Franco, Barbara Bagnato, Maria Giulia Marino, Cristina Meleleo, Laura Serino, Laura Zaratti

Abstract

Hepatitis B virus (HBV) infection is a serious global public health problem. The infection can be transmitted through sexual intercourse, parenteral contact or from an infected mother to the baby at birth, and, if contracted early in life, may lead to chronic liver disease, including cirrhosis and hepatocellular carcinoma. On the basis of the HBV carrier rate, the world can be divided in 3 regions of high, medium and low endemicity. The major concern is about high endemicity countries, where the most common route of infection remains vertical transmission from mother to child. Screening of all pregnant women and passive immunization with human hepatitis B immunoglobulin are not affordable for many developing countries. The infection rate can be reduced by modifying behavior, improving individual education, testing all blood donations, assuring asepsis in clinical practice and screening all pregnant women. However, availability of a safe and efficacious vaccine and adoption of appropriate immunization strategies are the most effective means to prevent HBV infection and its consequences. The unsolved problem for poorest countries, where the number of people currently infected is high, is the cost of the vaccine. A future challenge is to overcome the social and economic hurdles of maintaining and improving a prevention policy worldwide to reduce the global burden of the disease.

INTRODUCTION

Viral hepatitis type B is a common, serious disease caused by the hepatitis B virus (HBV), a partially double-stranded DNA virus of the Hepadnaviridae family. Four major serotypes (adr, ayr, ayw, and adw) and nine minor subtypes have been serologically identified at the hepatitis B surface antigen (HBsAg) level. The complete sequencing of DNA from HBV isolates worldwide has led to the identification of eight genotypes (from A to H) and a number of subgenotypes, showing different ethno/geographic distributions. HBV genotypes have also been associated with different clinical outcomes and response to interferon therapy. HBV is one of the main causes of hepatic cirrhosis and hepatocellular carcinoma.
decompensation, cirrhosis and hepatocellular carcinoma (HCC). Acute disease usually occurs when the immune response is well preserved, while patients with an immunodeficiency are more likely to develop a chronic disease, then becoming a source for new infections. The likelihood that an HBV infection become chronic depends upon the age at which a person is infected, infants and young children being the most likely to develop chronic infection.\(^1,2\)

HBV is carried in blood and other body fluids, including saliva, tears, semen and vaginal secretions. Depending on the epidemiological pattern within a geographic area, the main ways of transmission are sexual intercourse, parenteral contact or infection of the baby at birth from an infected mother. Globally, about one third of the population has been infected with HBV; six percent are chronic carriers and over 600,000 people die each year from acute disease or chronic sequelae secondary to HBV infection. On the basis of the HBV carrier rate, the world can be divided in to high, medium and low endemicity regions. The major concern is about high endemicity countries, especially in Asia and Africa, where the most common routes of infection remain vertical transmission from mother to child and horizontal transmission between children.\(^3,4\)

Vaccination is the most effective measure to reduce the global incidence of hepatitis B. Compared to other healthcare interventions, vaccination is an economically advantageous option, both in terms of cost-effectiveness and benefit-cost ratios. In 1991, the World Health Organization (WHO) recommended that all countries introduce a policy of universal hepatitis B vaccination to prevent and control HBV infection and its long term sequelae on a global scale. By the end of 2008, hepatitis B vaccine for infants was introduced nationwide in 177 countries. To date, global hepatitis B vaccine coverage is estimated at 69%.\(^5,6\)

GLOBAL PREVALENCE AND EPIDEMIOLOGY OF HEPATITIS B: FOCUS ON DEVELOPING COUNTRIES

HBV infection occurs all over the world. The WHO has estimated that there are more than 2 billion HBV infected people and about 378 million carriers worldwide. There are approximately 620,000 HBV related deaths each year. In addition, approximately 4.5 million new HBV infections occur worldwide each year, of which a quarter progresses to liver disease. In high endemic areas, like central Asian republics, Southeast Asia, Sub-Saharan Africa and the Amazon basin, the HBV carrier rate is over 8%. In low endemic regions, like the United States, Northern Europe, Australia and parts of South America, HBsAg prevalence is less than 2%. The Middle East, some Eastern European countries and the Mediterranean basin are considered areas of intermediate endemicity with a carrier rate between 2% and 8%.\(^7\)

In many countries, after the introduction of mass immunization campaigns, the prevalence of HBV notably changed, resulting in a decrease of the HBsAg carrier rate and HCC incidence.\(^2,3\) It was estimated that liver cancer represents approximately 4% of all new cancer cases diagnosed worldwide and that more than 50% of liver cancers were attributable to HBV. The highest age-adjusted incidence rate (> 20 per 100,000) was reported from Southeast Asian and Sub-Saharan African countries that are endemic for HBV infection. Up to 90% of infants infected during the first year of life and 30%-50% of children infected between one to four years of age develop chronic infections and about 25% of adults who become chronically infected during childhood die from HBV-related liver cancer or cirrhosis\(^8\).

HBV continues to be the major HCC risk factor worldwide, although its importance will continue to decrease during the next decades due to the widespread use of the HBV vaccine in newborns.\(^9,10\)

In the last few years, more and more data have been produced in developing countries and areas with high/intermediate endemicity where the most common route of infection is still vertical transmission from mother to child and horizontal transmission between children, particularly siblings\(^11,12,13\).

Globally, perinatal HBV transmission accounts for an estimated 21% of HBV-related deaths, while regionally it ranges from 13% in the Eastern Mediterranean region to 26% in the Western Pacific region. Recent studies in Africa confirm the relatively high HBsAg seroprevalence in pregnant women, irrespective of age, parity, gestational age, residence, history of blood transfusion, dental manipulation, tattooing and circumcision.\(^14\) The maternal-neonatal transmission was studied in Libya where HBsAg positivity was 1.5% and transmission 60.9% and in Ghana with a HBsAg prevalence of 16% but a materno-fetal transmission only in 8.4% of neonates.\(^15,16\)

In high endemic areas, other important modes of HBV transmission concern some high-risk groups such as health care workers (HCWs)\(^17-19\), but also sexual contacts\(^20\) and intravenous drug use\(^21-23\). The predominant ways of infection in areas of low endemicity play a role. Parenteral or percutaneous routes of HBV transmission, such as needle stick injury and mucus membrane splash in healthcare setting, as well as tattooing, piercing, sharing razors or toothbrushes, are also important in spreading the virus\(^24,25\). Surgery and dental care may be a source of infection; transfusion-related infections have currently become very rare in developed countries thanks to the improved serology and advances in molecular blood screening but can be an important source of infection in the poorest countries.\(^26-28\).

The prevalence of the infection in HCWs, a high risk group for acquiring infection with blood born pathogens due to occupational contact with infected body fluids, depends upon HBV prevalence in the general population. In India, an intermediate endemic zone where the estimated prevalence rate of HBV in the healthy general
population is around 4.7%, a recent study showed a 5% HBsAg positivity in HCWs, but a highest seropositivity of around 40% among laboratory technicians\[20\]. In Taiwan, among HCWs who were exposed to high risk patients, nearly 16% had HBV\[21\]. In north-west Turkey between 2002 and 2003, the occupational hazard of exposure to HBV was evaluated among 595 nurses. In total, 18.7% had been exposed to HBV infection and 2.7% were HBsAg positive. This result was in accordance with findings of several other studies, showing the level of prevalence for exposure to HBV among nurses to be between 16%-20%. In this study, 28% of nurses working in high risk departments were not vaccinated. Education plays a role in exposure to infection, with a decreasing trend from nurses that had received a normal high-school or equivalent education and those who had been educated to university standard\[22\].

Transfusion-related infections are an important source of HBV transmission, especially in the poorest countries. In countries with advanced medical, diagnostic and laboratory services, a large proportion of blood is used in sophisticated treatments requiring a high level of transfusion support, including chemotherapy, open heart surgery, organ transplantation and the management of hematological disorders such as leukemia, thalassemia and hemophilia. The pattern of blood usage is very different in countries where diagnostic and treatment options are more limited, with a much greater proportion of transfusions being given to women with obstetric emergencies and children suffering from severe anemia, often resulting from malaria and malnutrition. Data from WHO shows that, of the estimated 80 million units of blood donated annually worldwide, only 38% is collected in the developing world where 82% of the world’s population live\[46\].

In 2007, 162 countries provided data to WHO on 85.4 million blood donations. The data comes from countries that account for a total of 5.9 billion people, representing 92% of the global population. About one fourth of the countries are not able to screen all blood donations for one or more of the transfusion-transmissible infections, including HIV, hepatitis B, hepatitis C and syphilis; only 48% of blood donations in developing countries are screened following basic quality assurance procedures; only 25% of the hospitals performing transfusions in developing countries and 33% of the hospitals in transitional countries have a transfusion committee to monitor transfusion practices, compared to 88% of the hospitals in developed countries\[53\].

In Sub-Saharan Africa, the risk of transfusion-transmitted infections is thought to be substantial because of the high prevalence of these infections, the frequent use of paid or replacement donors and incomplete screening coverage\[49\]. In most Latin American and Asian countries, blood and blood products are now regularly screened for HBsAg; for example, in Brazil where the screening of blood became mandatory in 1993, the prevalence of HBsAg decreased significantly from 0.36% in 1998 to 0.14% in 2005 due to the better control of blood donors and the decreasing infection rate in the general population\[50\].

In the majority of the Latin American countries where endemity is intermediate/low, sexual intercourse is thought to be the most common route by which HBV infection is transmitted. In Brazil, a study from Victoria showed a HBV prevalence of 3.8% in HIV patients, while in other settings the prevalence rates ranged from 5.7% to 24.3%. While chronic HBV infection in the setting of HIV/AIDS is not considered an opportunistic infection, it is a common co-existing infection seen in HIV-infected individuals because of the shared modes of transmission\[20\].

Drug use is another important route of transmission of HBV. In Latin America, in low endemity areas, injectable drug-related and sexual transmission of hepatitis viruses are a significant problem among young, HIV-infected and heterosexual individuals, even if the use of parenteral drugs is not common in these regions\[53\].

## PREVENTION OF HEPATITIS B INFECTION

Prevention of HBV infection is a public health priority, especially for those groups at major risk of becoming chronic carriers.

Infection rate can be reduced through a modification of behavior and improving individual education. Testing of all blood donations and assuring asepsis in clinical practice reduce the risk of contracting HBV. Moreover, screening of all pregnant women helps to avoid mother to child transmission at birth. Administration of human hepatitis B immunoglobulin contributes to preventing neonatal infection and can be used after exposure to HBV as prophylaxis. Vaccination is the most effective means of preventing hepatitis B, cirrhosis and hepatocellular carcinoma worldwide\[46-51\].

The first vaccines, available between 1981 and 1982, were produced by harvesting the hepatitis B surface antigen from plasma of chronic HBsAg carriers and contained highly purified 22 nm HBsAg particles inactivated through a combination of urea, pepsin, formaldehyde and heat. These immunogenic plasma-derived vaccines have been used with success in several hundred million individuals and are still produced in Asia and used in a number of countries. Concern about the safety of these vaccines regarding transmission of blood-borne pathogens has proved to be unfounded. In the mid 1980s, recombinant DNA hepatitis B vaccines containing HBsAg expressed in HBV transfected yeasts (i.e. *Saccharomyces cerevisiae*), the so-called “second” generation hepatitis B vaccine, were commercialized. This new technology offered the potential of unlimited production, which allowed the hepatitis B vaccine to become one of the most widely used in the world. Several hundred million doses of hepatitis B vaccine have been administered worldwide with an excellent record of safety and efficacy. Similar results were obtained in India, where a new recombinant DNA HBV vaccine was produced\[52-54\].

Following a full course of vaccination (3 doses given at 0, 1 and 6 mo), seroprotection rates of antibodies against HBsAg (anti-HBs) are close to 100% in children.
and almost 95% in healthy young adults. People who are elderly, obese, heavy smokers or immunocompromised, including those infected with HIV, may have suboptimal responses when vaccinated. Immunodeficient patients, such as those undergoing hemodialysis or immunosuppressant therapy, require higher doses of vaccine and more injections (i.e. at months 0, 1, 2 and 6) to achieve an adequate immune response. Rapid protection (i.e. for health care workers exposed to HBV or a susceptible sexual partner of an acute hepatitis B patient) can be achieved through the adoption of an accelerated schedule, including 3 doses of vaccine administered at 0, 1 and 2 mo, followed by a booster dose given at 12 mo. The site of injection and mode of administration are critical factors in achieving an optimal response. The vaccine should be given intramuscularly into the deltoid region in children (≥1 year of age) and adults or into the anterolateral thigh in newborns and infants (< 1 year of age). The intradermal route and buttock administration are not recommended. Hepatitis B vaccines are well tolerated. Side effects are generally mild, transient and confined to the site of injection (erythema, swelling, induration). Systemic reactions (fatigue, slight fever, headache, nausea, abdominal pain) are uncommon. However, in recent years, the safety of the hepatitis B vaccine has been questioned, but extensive studies concluded that there is no reason to change the current policies of vaccination. Hepatitis B vaccination is not contraindicated in pregnant or lactating women. The only absolute contraindications are known hypersensitivity to any component of the vaccine or a history of anaphylaxis to a previous dose.

Follow-up studies have shown that the vaccine-induced antibody persists over periods of at least 10-15 years and that the duration of anti-HBs is related to the antibody peak level achieved after primary vaccination. Follow-up of those vaccinated has shown that the antibody concentrations usually decline over time but clinically significant breakthrough infections are rare. Evidence indicates that successfully vaccinated individuals who have lost their antibodies over time usually show a rapid anamnestic response when boosted with an additional dose of vaccine or when exposed to the HBV. This means that the immunological memory for HBsAg can outlast the anti-HBs detection, providing long-term protection against acute disease and the development of an HBsAg carrier state. For immunocompromised patients, regular testing and booster administrations when anti-HBs antibody level falls below 10 mIU/mL are recommended instead.

Antibodies to the hepatitis B surface antigen are mainly targeted to bind the amino acid hydrophilic region, referred to as a determinant of HBsAg. This provides protection against infection with all HBV genotypes and is responsible for the broad immunity afforded by hepatitis B vaccination. The emergence of HBV S-gene mutants possibly able to escape the vaccine-induced response was suggested. However, at least at present, the overall impact of such mutants remains low and they do not pose a public health threat or a need to modify the established hepatitis B vaccination programs.[55–57]

STRATEGIES FOR PREVENTION OF HEPATITIS B INFECTION SUITABLE FOR DEVELOPING COUNTRIES

In 1991, WHO recommended that all countries with a high hepatitis B disease burden should introduce the hepatitis B vaccine in their routine immunization programs by 1995 and all other countries by 1997. However, uptake of the vaccine was slow and the targets were not met. Even when the initial high price of the vaccine came down substantially, most low-income countries were unable to secure the funds needed to introduce the vaccine. Before the launch of GAVI (Global Alliance for Vaccines and Immunization) in 2000, less than 10% of the world’s poorest countries were using hepatitis B vaccine in their routine immunization programs.

With support from GAVI through its financing arm, The Vaccine Fund, by December 2003, over 42 million children in low-income countries had been immunized with hepatitis B vaccine; as a result, over 500,000 premature death deaths from hepatitis B have been prevented among children born in 2001-2003.[54].

The most recent available data show global hepatitis B vaccine coverage at 69% with the following regional distribution: 67% in the African region; 76% in the European region; 81% in the Eastern Mediterranean region; 88% in the Americas; and 89% in the Western Pacific. Coverage in the South-East Asia region increased from 29% to 41% from 2007 to 2008. The immunization coverage with the 3rd dose of Hepatitis B vaccines in infants, in 2009, for country is: ≥ 90% (108 countries or 56%, most of them in low endemic areas); 80%-89% (31 countries or 16%); 50%-79% (31 countries or 16%); < 50% (7 countries or 4%); Hepatitis B not on schedule (16 countries or 8%)[58].

In 2005, the World Health Assembly approved and the United Nations Children’s Fund (UNICEF) Executive Board endorsed the Global Immunization Vision and Strategy (GIVS). The primary objective of GIVS was to reduce vaccine-preventable disease mortality and morbidity by two-thirds by 2015 compared to 2000.

A mathematical model was developed to estimate the cost required to reach this goal in 117 low- and lower-middle-income countries and the study conclusions were that, in the 72 poorest countries, up to 40% of the overall resource needs were unmet.[59]

WHO recommends that all countries introduce the hepatitis B vaccine into routine national infant immunization programs. Furthermore, in countries where a high proportion of infections with HBV are acquired perinatally (specifically in countries where the prevalence of chronic HBV infection in the general population is ≥ 8%), WHO recommends the first dose of hepatitis B vaccine be given as soon as possible after birth (< 24 h) to prevent perinatal HBV transmission.

In 2006, birth-dose coverage varied widely by region,
from 3% to 71%. Birth-dose coverage for states with 
\[ \geq 8\% \] prevalence of chronic HBV infection was 36% 
(range by region, 1%-92%), and for countries with < 8% 
prevalence, it was 20%. Among the 81 states with immu-
nization schedules that include a birth dose of hepatitis 
B vaccine, 22 (27%) did not report coverage data on the 
birth dose. It is likely that the reporting of the coverage 
of newborns with hepatitis B vaccine through the report-
ing form could be improved\[57\].

When introducing the hepatitis B vaccine into infant 
immunization programs, national policy-makers must 
decide when to begin the vaccine series: (1) at birth for 
all infants; (2) at birth but targeted only at newborns 
of HBV-infected women; or (3) at the same time in the 
immunization schedule as other vaccines are administered 
for all infants (for example, at 6 wk when other vaccines 
in the Expanded Program on Immunization are initi-
ated), which is too late to prevent perinatal HBV infec-
tion. Administering a birth dose of hepatitis B vaccine 
only to newborns of HBV-infected women is usually not 
feasible in developing countries where the endemicity 
is high; this strategy is prone to error and misses post-
exposure prophylaxis of infants, even in countries where 
testing and identifying infected women during pregnancy 
are well established. Additionally, it fails to provide early 
pre-exposure protection to babies born to uninfected 
women who may live with infected household contacts.

Administering hepatitis B vaccine to infants within 24 h 
after birth is logistically challenging for several reasons. 
Firstly, many infants, especially in remote or poor areas, 
are born at home without the services of skilled atten-
dants and therefore no trained providers are present to 
administer immunizations. Secondly, infant vaccines are 
usually given by specialized providers in well-baby clinics 
or other outpatient health settings, or during outreach 
immunization sessions in the community, but care of 
mothers during delivery and of infants immediately after 
birth is often provided by maternal health workers; so 
administering a birth dose of hepatitis B vaccine requires 
the coordination of these two types of workers. Thirdly, 
in many parts of the world, vaccines are delivered from 
central stores to peripheral clinics at monthly or at even 
longer intervals; these are primarily intended for use dur-
ing periodic immunization sessions. Thus, the hepatitis 
B vaccine needed for the birth dose may not be available 
every day for administration to newborns.

Interventions that could improve birth-dose coverage 
include: increasing the number of infants born in facili-
ties or attended by skilled health staff; improving coordi-
nation between immunization staff and maternal health 
staff; integrating delivery of the birth dose of hepatitis B 
vaccine into part of essential newborn care; improving 
the reach of the cold chain; exploring options for deliv-
ering the vaccine to infants born and residing in areas 
beyond the cold chain; and conducting health promotion 
and training to improve awareness among providers and 
parents of the importance of administering hepatitis B 
vaccine within 1 d after birth\[2,14-20\].

Immunizing newborns with the hepatitis B vaccine 
should be the highest priority in highly endemic areas 
where the contribution of perinatal transmission to the 
overall disease burden is greatest. Nevertheless, even in 
countries with < 8% prevalence of chronic HBV infec-
tion, vaccinating newborns may be an important control 
strategy. Disease modeling suggests that the implementa-
tion of a birth dose of hepatitis B vaccine in WHO re-
gions with a relatively low prevalence of chronic HBV in-
festation, such as the Americas or Europe, will result in an 
additional 10%-20% reduction in HBV mortality in those 
regions compared with a hepatitis B vaccination schedule 
without a birth dose\[57,58\].

Post-exposure prophylaxis was thoroughly studied in 
infects born to HBeAg-positive HBsAg carrier mothers. 
The efficacy of protecting from chronic HBsAg carriage 
with passive-active immunoprophylaxis in these infants 
is more than 90%. In the case of hepatitis B immune 
globulin (HBIG) being skipped, active immunization is 
still effective, but the effectiveness of protecting from 
chronic HBV infection decreases slightly to more than 
83%. The other means to increase the effectiveness of 
immunization against perinatal mother-to-infant HBV 
failure is to give HBIG to newborns of all HBsAg car-
rier mothers, as is done in the United States and in most 
European countries, but the costs rises considerably.

Although immunizing with universal vaccination is 
the only way to control HBV infection, recent advances 
in the specific treatment have enabled suppression of 
the chronic viral infection. Because humans are the only 
reservoir of the virus, if HBV could be eradicated or 
strongly and effectively suppressed in human carriers, 
the spread of HBV would be prevented.

Chronic hepatitis B can be treated by α-interferon 
(IFN-α; regular or pegylated) or nucleoside analogs. 
In properly chosen patients with chronic hepatitis B, 
30%-40% will have a sustained virological response 6-12 
mo after IFN-α treatment. More importantly, 30%-70% of 
the initial virological responders will clear serum HBs-
Ag on follow up. The wide range of HBsAg clearance 
may be due to different durations of follow up, different 
treatment regimes, different distributions of HBV geno-
types and different ethnic background of the patients. Se-
rvonegativity of HBsAg has very important implications: 
it signifies a better prognosis for patients and a much 
lower infectivity of the previous HBsAg carrier. The oral 
nucleoside analogs are effective and very well-tolerated. 
At present, these treatments are indicated for HBV car-
rriers with disease activities; nevertheless, there may be 
exceptions: because high maternal viral load of HBV is 
the most critical factor in perinatal HBV transmission, 
even after on-schedule immunoprophylaxis, lowering the 
mortalit of maternal viral load by antiviral therapy may reduce 
the perinatal HBV infection\[59\].

**CONCLUSION**

In spite of the decrease of the burden related to HBV
infection due to the adoption of mass immunization campaigns all over the world, the number of people still currently infected, especially in developing countries, will represent a public health concern in the foreseeable future. Improving prevention policy worldwide is mandatory in order to reduce the global burden of the disease. A substantial number of WHO member states in areas with low or intermediate hepatitis B endemicity have implemented vaccination of newborns with the hepatitis B vaccine. Consideration should be given to implementing routine vaccination of newborns against HBV infection globally to prevent mortality and morbidity due to infection acquired perinatally.

Unfortunately, screening of all pregnant women and the use of human hepatitis B immunoglobulin as passive immunization is not affordable for many developing countries, so child vaccination remains the only means to prevent HBV spreading.

With its relatively modest costs and high benefits, HBV immunization continues to be one of the best values for public health investment today.

Moreover, enforced testing for HBsAg of blood donations in those countries where it is not a universal requirement yet could be an important measure to prevent infections in clinical settings, as well as maintaining asepsis in invasive techniques and vaccination for high risk groups.

A future challenge is to overcome the social and economic hurdles to maintain and improve prevention policy worldwide to reduce the global burden of the disease.

REFERENCES

1 WHO. Department of Communicable Diseases Surveillance and Response. Hepatitis B. Available from: URL: http://www.who.int/csr/disease/hepatitis/HepatitisB_whoecdcsrlyo2002_2.pdf
2 Zanetti AR, Van Damme P, Shouval D. The global impact of vaccination against hepatitis B: a historical overview. Vaccine 2008; 26: 6266-6273
3 Global Immunization Data, October 2009. Available from: URL: http://www.who.int/immunization_monitoring/data/en/
4 WHO. Expanded Programme on Immunization Hepatitis B Vaccine. Available from: URL: http://www.who.int/vaccines-documents/DoxNews/updates/updated3e.pdf
5 Viviani S, Carrieri P, Bah E, Hall AJ, Kirk GD, Mendy M, Montesano R, Plymouth A, Sam O, Van der Sande M, Whittle H, Hainaut P, Gambia Hepatitis Intervention Study. 20 years into the Gambia Hepatitis Intervention Study: assessment of initial hypotheses and prospects for evaluation of protective effectiveness against liver cancer. Cancer Epidemiol Biomarkers Prev 2008; 17: 3216-3223
6 Anwar WA, Khaled HM, Amra HA, El-Nezami H, Loffredo CA. Changing pattern of hepatocellular carcinoma (HCC) and its risk factors in Egypt: possibilities for prevention. Mutat Res 2008; 659: 176-184
7 Rikabi A, Bener A, Al-Marri A, Al-Thani S. Hepatitis B and C viral infections in chronic liver disease: a population based study in Qatar. East Mediterr Health J 2009; 15: 778-784
8 Fassio E, Míguez C, Soría S, Palazzo F, Gadano A, Adrover R, Landete G, Fernández N, García D, Barbero R, Perelstein G, Ríos B, Isla R, Civeita E, Pérez Ravier R, Barzola S, Curiarello J, Colombato LA, Jemnitzky A. Etiology of hepatocellular carcinoma in Argentina: results of a multicenter retrospective study. Acta Gastroenterol Latinoam 2009; 39: 47-52
9 Mendy ME, Welzel T, Lesi OA, Hainaut P, Hall AJ, Kuni-holm MH, McConkey S, Goedert JJ, Kaye S, Rowland-Jones S, Whittle H, Kirk GD. Hepatitis B viral load and risk for liver cirrhosis and hepatocellular carcinoma in The Gambia, West Africa. J Viral Hepat 2010; 17:115-122
10 Nordenstedt H, White DL, El-Serag HB. The changing pattern of epidemiology in hepatocellular carcinoma. Dig Liver Dis 2010; 42 Suppl 3: S206-S214
11 McClune AC, Tong MJ. Chronic hepatitis B and hepatocel-lular carcinoma. Clin Liver Dis 2010; 14: 461-476
12 Asia-Pacific Working Party on Prevention of Hepatocel-lular Carcinoma. Prevention of hepatocellular carcinoma in the Asia-Pacific region: consensus statements. J Gastroenterol Hepatol 2010; 25: 657-663
13 Kew MC. Epidemiology of chronic hepatitis B virus infec-tion, hepatocellular carcinoma, and hepatitis B virus-induced hepatocellular carcinoma. Pathol Biol (Paris) 2010; 58: 273-277
14 Elsheikh RM, Daak AA, Elsheikh MA, Karsany MS, Adam I. Hepatitis B virus and hepatitis C virus in pregnant Sudanese women. Virol J 2007; 4: 104
15 Candotti D, Danso K, Allain JP. Maternofetal transmission of hepatitis B virus genotype E in Ghana, west Africa. J Gen Virol 2007; 88: 2686-2695
16 Lima LH, Viana MC. Prevalence and risk factors for HIV, syphilis, hepatitis B, hepatitis C, and HTLV-I/Il infection in low-income postpartum and pregnant women in Greater Metropolitan Vitória, Espírito Santo State, Brazil. Cad Saude Publica 2009; 25: 668-676.
17 Chae HB, Kim JH, Kim JK, Yim HJ. Current status of liver diseases in Korea: hepatitis B. Korean J Hepatol 2009; 15 Suppl 6: S13-S24
18 Shrestha P, Bhandari D, Sharma D, Bhandari BP. A study of viral hepatitis during pregnancy in Nepal Medical College Teaching Hospital. Nepal Med Coll J 2009; 11: 192-194
19 El-Magræhe H, Furarah AR, El-Figih K, El-Urshafany S, Ghenghesh KS. Maternal and neonatal seroprevalence of Hepatitis B surface antigen (HBsAg) in Tripoli, Libya. J Infect Dev Ctries 2010; 4: 168-170
20 Zhang S, Li RT, Wang Y, Liu Q, Zhou YH, Hu Y. Seropreva-lence of hepatitis B surface antigen among pregnant women in Jiangsu, China, 17 years after introduction of hepatitis B vaccine. Int J Gynaecol Obstet 2010; 109: 194-197
21 Ganju SA, Goel A. Prevalence of HBV and HCV infection among health care workers (HCWs). J Commun Dis 2000; 32: 228-230
22 Shiao J, Guo L, McLawes ML. Estimation of the risk of blood-borne pathogens to health care workers after a needlestick injury in Taiwan. Am J Infect Control 2002; 30: 15-20
23 Kosgeroglou N, Ayarinci U, Vardareli E, Dincer S. Occupa-tional exposure to hepatitis infection among Turkish nurses: frequency of needle exposure, sharps injuries and vaccina-tion. Epidemiol Infect 2004; 132: 27-33
24 Pereira LM, Martelli CM, Merchán-Hamann E, Montarroryos UR, Braga MC, de Lima ML, Cardoso MR, Turchi MD, Costa MA, de Alencar LC, Moreira RC, Figueiredo GM, Xinemes RA. Population-based multicentric survey of hepatitis B infection and risk factor differences among three regions in Brazil. Am J Trop Med Hyg 2009; 81: 240-247
25 Ziraba AK, Bwogi J, Namale A, Wainaina CW, Mayanja-Kiz za H. Sero-prevalence and risk factors for hepatitis B virus infection among health care workers in a tertiary hospital in Uganda. BMC Infect Dis 2010; 10: 191
26 Zago AM, Machado TF, Cazarni FL, Miranda AE. Preva-lence and risk factors for chronic hepatitis B in HIV patients attended at a sexually-transmitted disease clinic in Vitória, Brazil. Braz J Infect Dis 2007; 11: 475-478
27 Tanaka J. Hepatitis B epidemiology in Latin America. Vac-cine 2005; 18 Suppl 1: S17-S19
Franco E et al. Hepatitis B in developing countries

28 Nunes CL, Andrade T, Galvão-Castro B, Bastos FL, Reingold A. Assessing risk behaviors and prevalence of sexually transmitted and blood-borne infections among female crack cocaine users in Salvador--Bahia, Brazil. Braz J Infect Dis 2007; 11: 561-566

29 Nyirenda M, Beadsworth MB, Stepney P, Hart CA, Hart JL, Munthali C, Beeching NJ, Zijlstra EE. Prevalence of infection with hepatitis B and C virus and coinfection with HIV in medical inpatients in Malawi. J Infect 2008; 57: 72-77

30 Pérez CC, Cerón AI, Fuentes LG, Zahartu SC, Balcells M ME, Ajenjo HC, Rabagliati BR, Labarca LJ, Acuña LG. [Hepatitis B, C, Treponema pallidum and Toxoplasma gondii co-infections in HIV infected patients]. Rev Med Chil 2009; 137: 641-648

31 Ferreira RC, Rodrigues FP, Teles SA, Lopes CL, Motta-Castro AR, Novais AC, Souto FJ, Martins RM. Prevalence of hepatitis B virus and risk factors in Brazilian non-injecting drug users. J Med Virol 2009; 81: 602-609

32 Lamar JR, Agurto HS, Guanira JV, Ganoza C, Casapia M, Ojeda N, Ortiz A, Zamalloa V, Suarez-Ogno L, Cabezas C, Sanchez JL, Sanchez J. Hepatitis B infection and association with other sexually transmitted infections among men who have sex with men in Peru. Am J Trop Med Hyg 2010; 83: 194-200

33 Ashraf H, Alam NH, Rothermundt C, Brooks A, Bardhan P, Hossain L, Salam MA, Hassan MS, Beglinger C, Gyr N. Prevalence and risk factors of hepatitis B and C virus infections in an impoverished urban community in Dhaka, Bangladesh. BMC Infect Dis 2010; 10: 208

34 Lin CF, Twu SJ, Chen PH, Cheng JS, Wang JD. Prevalence and determinants of hepatitis B antigenemia in 15,007 in-mates in Taiwan. J Epidemiol 2010; 20: 231-236

35 Mahfoud Z, Kassak K, Kreidieh K, Shamra S, Ramia S. Prevalence of antibodies to human immunodeficiency virus (HIV), hepatitis B and hepatitis C and risk factors in prisoners in Lebanon. J Infect Dev Ctries 2010; 4: 144-149

36 Andrade AF, Oliveira-Silva M, Silva SC, Motta IJ, Bonvicini CR. Seroprevalence of hepatitis B and C virus markers among blood donors in Rio de Janeiro, Brazil, 1998-2005. Mem Inst Oswaldo Cruz 2006; 101: 673-676

37 WHO. Global Blood Safety and Availability - Key facts and figures from the 2007 Blood Safety Survey. Available from: URL: http://www.who.int/mediacentre/factsheets/fs279/en/print.html

38 Nascimento MC, Mayaud P, Sabino EC, Torres KL, Franchesci S. Prevalence of hepatitis B and C serological markers among first-time blood donors in Brazil: a multi-center serosurvey. J Med Virol 2008; 80: 53-57

39 Abou MA, Eltahir YM, Ali AS. Seroprevalence of hepatitis B virus and hepatitis C virus among blood donors in Nyla, South Dar Fur, Sudan. Virol J 2009; 6: 146

40 Tessema B, Yismaw G, Kassu A, Amsalu A, Mulu A, Emmrich F, Sack U. Seroprevalence of HIV, HBV, HCV and syphilis infections among blood donors at Gondar University Teaching Hospital, Northwest Ethiopia: declining trends over a period of five years. BMC Infect Dis 2010; 10: 111

41 Jayaraman S, Chalabi Z, Perel P, Guerrero C, Roberts I. The risk of transfusion-transmitted infections in sub-Saharan Africa. Transfusion 2010; 50: 433-442

42 Yuen MF, Lee CK, Wong DK, Fung J, Hung I, Hsu A, But DY, Cheung TK, Chan P, Yuen JC, Fung FK, Seto WK, Lin CK, Lai LF. Prevalence of occult hepatitis B infection in a highly endemic area for chronic hepatitis B: a study of a large blood donor population. Gut 2010; 59: 1389-1393

43 Azar A, Kamali S, Altunay H, Kosen O, Oncul O, Gorenek L, Cavuslu S. HBV, HCV and HIV seroprevalence among blood donors in Istanbul, Turkey: how effective are the changes in the national blood transfusion policies? Braz J Infect Dis 2010; 14: 41-46

44 WHO. Blood Transfusion Safety Available from: URL: http://www.who.int/bloodsafety/en/Blood_Transfusion_Safety.pdf

45 Tiwari BR, Ghimire P, Kandel SR, Rajkarnikar M. Seroprevalence of HBV and HCV in blood donors: A study from regional blood transfusion services of Nepal. Asian J Transfus Sci 2010; 4: 91-93

46 Rani M, Yang B, Nesbit R. Hepatitis B control by 2012 in the WHO Western Pacific Region: rationale and implications. Bull World Health Organ 2009; 87: 707-713

47 Mandeville KL, Krabshuis J, Ladeq NG, Mulder CJ, Quigley EM, Khan SA. Gastroenterology in developing countries: issues and advances. World J Gastroenterol 2009; 15: 2839-2854

48 Lu J, Zhou Y, Lin X, Jiang Y, Tian R, Zhang Y, Wu J, Zhang F, Zhang Y, Wang Y, Bi S. General epidemiological parameters of viral hepatitis A, B, C, and E in six regions of China: a cross-sectional study in 2007. PloS One 2009; 4: e8467

49 Voigt AR, Strazzer Neto M, Spada C, Treitinger A. Seroprevalence of hepatitis B and hepatitis C markers among children and adolescents in the south Brazilian region: metropolitan area of Florianópolis, Santa Catarina. Braz J Infect Dis 2010; 14: 60-65

50 Park NH, Chung YH, Lee HS. Impacts of vaccination on hepatitis B viral infections in Korea over a 25-year period. Intervirology 2010; 53: 20-28

51 Alaviani SM, Fallahiyan F, Lankarani KB. Implementing strategies for hepatitis B vaccination. Saudi J Kidney Dis Transpl 2010; 21: 10-22

52 Abraham P, Mistry FP, Bapat MR, Sharma G, Reddy GR, Prasad KS, Ramanna V. Evaluation of a new recombinant DNA hepatitis B vaccine (Shanvac-B). Vaccine 1999; 17: 1125-1129

53 Thakur V, Pati NT, Gupta RC, Sarin SK. Efficacy of Shanvac-B recombinant DNA hepatitis B vaccine in health care workers of Northern India. Hepatobiliary Pancreas Dis Int 2010; 9: 393-397

54 GAVI hepatitis B fact sheet 2005. Available from: URL: http://www.gavi.org/intervention_delivery/adc/gavi_hepb_factsheet.pdf

55 Global Immunization Data, October 2009. Available from: URL: http://www.who.int/bloodsafety/en/Blood_Transfusion_Safety..

56 Wolkoff AJ, Gasse F, Lee-Martin SP, Lydon P, Magan A, Toubi A, Johns A, Hutubessy R, Salamab P and Okwo-Beled JM. Estimating the costs of achieving the WHO-UNICEF global Immunization Vision and Strategy, 2006-2015. Bull World Health Organ 2008; 86: 27-39

57 Goldstein ST, Zhou F, Hadler SC, Bell BP, Mast EE and Margolis HS. A mathematical model to estimate global hepatitis B disease burden and vaccination impact. Int J Epidemiol 2005; 34: 1329-1339

58 Worldwide implementation of hepatitis B vaccination of newborns, 2006. Weekly epidemiological record 2008; 83: 429-440. Available from: URL: http://www.who.int/wer

59 Chen DS. Toward elimination and eradication of hepatitis B. J Gastroenterol Hepatol 2010; 25: 19-25

S-Editor Wu X  L-Editor Roemmele A  E-Editor Wu X